GB Sciences (OTCMKTS: GBLX) is taking innovative strategies to accelerate the process of drug development through proprietary biopharma tech. In addition, the company is creating strategic partnerships to advance the development of its proprietary, plant-based treatments for the prescription drug industry.
PhAROS accelerating the discovery process
The company uses a revolutionary drug development platform called PhAROS to accelerate the discovery process. PhAROS stands for Phytomedical Analytics for research Optimization at Scale, and the platform predicts proprietary formulations of plant-based therapeutic mixtures. Notably, the platform combines convention plant-based medicines’ wisdom with the latest data analytics and machine learning, allowing the company to cut the time and money needed to deliver proprietary plant-based therapies to the market.
GB Sciences Chief Scientific Officer and President Dr. Andrea Small-Howard said, “Our research and development processes are very innovative because we know that the development of novel drugs through traditional biopharmaceutical pipelines is very slow. It typically takes at least 10 years for a new medicine to go from the initial discovery phase to the marketplace, and during that time, millions are left hoping and waiting for symptom relief.”
The proprietary platform cuts drugs discovery time from seven to 1.5 years
The company’s new approach to drug discovery improves research efficiency and cuts its time to develop therapeutic candidates from seven to 1.5 years. Gb Sciences uses its PhAROS drug discovery platform to identify and predict the efficacy of plant-based therapeutic mixtures for specific illnesses in silico and then evaluates the minimum essential mixtures from plants in cell and animal models of certain diseases using robotics-assisted screening of plant mixtures.
The company has identified and validated exact combinations of plant-based molecules to treat illnesses such as neurological disorders, anxiety, inflammation, depression, metabolic syndrome, chronic pain, and heart disease using both PhAROS and high throughput screening devices. Gb Sciences has made significant progress in its drug discovery and product development activities as due to the combination approach. Already the company has received three US patents covering its primary therapeutics for Parkinson’s disease, chronic pain, and inflammation.
Affinor Growers Inc. (OTCMKTS: RSSFF) Closes Non-Brokered Placement of 10.43 Million Units And Appoints Patrick Carey To Board
Post Views: 4 Affinor Growers Inc. (OTCMKTS: RSSFF) has announced the closing of a non-brokered placement of 10.43 million units...
CEA Industries Inc. (OTCMKTS: SRNA) Announce $2.1 million contract with a Maryland facility
Post Views: 36 CEA Industries Inc. (OTCMKTS: SRNA), which does business as Surna Cultivation Technologies, has announced that it received...
Decibel Cannabis Company Inc. (OTCMKTS: DBCCF) Expanding Recreational Cannabis Market Share And Announced Debt Refinancing
Post Views: 43 Decibel Cannabis Company Inc. (OTCMKTS: DBCCF) has offered an update about its latest Canadian recreational market share. ...
Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) Expanding Leadership In Cannabis 2.0- Sales With Increase In Market Share To 15%
Post Views: 56 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has reported ongoing nationwide leadership in Cannabis 2.0 sales in 2021...
Ayr Wellness (OTCMKTS: AYRWF) Opens New Cannabis Dispensary in Pinellas, Florida, its 44th Location In The State
Post Views: 5 Ayr Wellness (OTCMKTS: AYRWF) has announced the opening of its latest dispensary in Pinellas, Florida. The Pinellas...
CLS Holding USA Inc. (OTCMKTS: CLSH) Announces 10% Revenue Growth in Q2 2022 As It Tops Concentrate Sales In Nevada
Post Views: 72 CLS Holding USA Inc. (OTCMKTS: CLSH), which operates as Cannabis Life Sciences, has announced its financial and...